Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-snake venom serum
- Development stage
- Unknown
- Lead developer
- Mediclone Biotech
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Anti-snake venom serum (ASVS) developed by Mediclone Biotech Private Limited is a polyvalent, equine-derived polyclonal antiserum biologic used for the treatment of snake envenomation. The product contains purified immunoglobulin fragments (typically F(ab')2) obtained from the plasma of horses immunized against the venom of the "Big Four" venomous snake species found in India: the Indian Cobra (*Naja naja*), Russell's Viper (*Daboia russelii*), Saw-scaled Viper (*Echis carinatus*), and Common Krait (*Bungarus caeruleus*). Administered intravenously, these polyclonal antibodies bind to and neutralize various snake venom toxins, preventing them from reaching their physiological targets and mitigating systemic toxicity. Mediclone Biotech manufactures this therapeutic at its WHO GMP-compliant facility in Chennai and exports it to several countries in Africa and Asia, including Kenya, Bangladesh, and Egypt.
- Brand names
- SVAS
- Other names
- ASVSAnti-snake venom serumSnake Venom Anti SerumPolyvalent Anti Snake Venom Serum
02
Targets
PLA2 (Phospholipase A2 group IID)SVMP (Snake venom metalloproteinase)
Beyond the preview
Go deeper on Anti-snake venom serum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-snake venom serum.